Form 8-K - Current report:
SEC Accession No. 0000950170-24-127107
Filing Date
2024-11-14
Accepted
2024-11-14 16:27:47
Documents
15
Period of Report
2024-11-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aktx-20241113.htm   iXBRL 8-K 101278
2 EX-4.1 aktx-ex4_1.htm EX-4.1 159242
3 EX-10.1 aktx-ex10_1.htm EX-10.1 366616
4 EX-99.1 aktx-ex99_1.htm EX-99.1 20594
5 EX-99.2 aktx-ex99_2.htm EX-99.2 682702
  Complete submission text file 0000950170-24-127107.txt   1690185

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20241113.xsd EX-101.SCH 97669
17 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20241113_htm.xml XML 6056
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 241463008
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)